SCHEMBL11027974

SCHEMBL11027974

CN1CCN(c2ccc(Nc3cc(Br)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 3/20 0.54
▸ MAPKAPK2 P49137 2/20 0.52
▸ CDK2 P24941 3/20 0.51
▸ AURKA O14965 2/20 0.51
▸ CCNA2 P20248 2/20 0.51
▸ CDK4 P11802 1/20 0.51
▸ CCND3 P30281 1/20 0.51
▸ CDK6 Q00534 1/20 0.51
▸ PIM1 P11309 1/20 0.49
▸ TTK P33981 1/20 0.49
▸ PIM2 Q9P1W9 1/20 0.49
▸ SYK P43405 2/20 0.49
▸ EGFR P00533 1/20 0.48
▸ LCK P06239 1/20 0.47
▸ BTK Q06187 1/20 0.47
▸ STAT6 P42226 1/20 0.46
▸ CCNA1 P78396 1/20 0.46
▸ FLT3 P36888 2/20 0.46
▸ ALK Q9UM73 3/20 0.46
▸ EML4 Q9HC35 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23080983 0.85 LCK (0.54) SLC2A1CDK2AURKACCNA2CDK4
SCHEMBL11031861 0.84 SLC2A1 (0.55) SLC2A1MAPKAPK2CDK2AURKACCNA2
SCHEMBL11029599 0.84 MAPKAPK2 (0.58) SLC2A1MAPKAPK2CDK2AURKACCNA2
SCHEMBL11029725 0.83 CCNA2 (0.58) CDK2CCNA2CDK4CDK6PIM1
SCHEMBL11031767 0.82 SLC2A1 (0.50) SLC2A1MAPKAPK2CDK2AURKACCNA2
SCHEMBL11030064 0.82 CHEK1 (0.56) SLC2A1MAPKAPK2CDK2AURKACCNA2
SCHEMBL11026741 0.81 FYN (0.55) SLC2A1MAPKAPK2CDK2AURKACCNA2
SCHEMBL11029346 0.81 MAPKAPK2 (0.61) SLC2A1MAPKAPK2CDK2AURKACCNA2
SCHEMBL11028611 0.81 SLC2A1 (0.51) SLC2A1MAPKAPK2CDK2AURKACCNA2
SCHEMBL11030049 0.81 SLC2A1 (0.51) SLC2A1MAPKAPK2CDK2AURKACCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 SLC2A1 3662/4885MAPKAPK2 115/4885CDK2 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback